posted
If it has enough buying power it won't matter right IMAKE? You dagone daytraders don't do any DD anyway!! j/k lol!!!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology Announces Completion of Pre-IND Meeting with the FDA for RPE Therapy for the Treatment of Retinal Degenerative Disease
Feb 1, 2008 09:28:01 (ET)
LOS ANGELES, Feb 01, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that it completed discussions with the Food and Drug Administration (FDA) regarding its retinal pigmented epithelial (RPE) cell therapy through a type B, pre-Investigational New Drug (pre-IND) meeting concerning the regulatory pathway and requirements to file an IND to initiate human clinical trials. ACT is working with the agency to fulfill the FDA's requirements to bring its RPE cell therapy into human clinical trials for the treatment of retinal degenerative diseases such as Retinitis Pigmentosa, Stargardt's disease, and dry age-related macular degeneration (AMD). The RPE cells are derived from human embryonic stem cells created from ACT single blastomere cell lines under GMP compliant conditions. ACT is moving forward with its characterized RPE manufacturing process to complete the final stages of the company's preclinical testing. Should ACT successfully file an IND for its RPE therapy, the company plans to move forward with Phase I human clinical trials. ACT's Myoblast therapy, an autologous adult stem cell therapy for the treatment of heart failure, has already successfully completed Phase I human clinical trials and is moving into Phase II human clinical trials shortly.
Studies of the company's proprietary RPE cells have shown that the therapy may ultimately provide effective treatment of degenerative retinal disorders including macular degeneration, which represents a $28 billion dollar market. AMD affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 in the United States. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 have the condition. To date, AMD patients have had few if any effective therapies for treatment; thus, the need for novel therapies is clear.
In November at Neuroscience 2007, researchers at Oregon Health and Science University (OHSU) presented results of a study that used ACT RPE cells manufactured under GMP conditions (21CFR211) at the company's facility in Worcester, Massachusetts. The RPE cells were thoroughly characterized and cryo-preserved and shipped to researchers at OHSU for transplantation. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing ACT's GMP-manufactured human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like AMD, where RPE function is compromised.
The next step in the development of the program will be to complete several safety studies utilizing the GMP-manufactured RPE cells. Pilot studies to date have shown the cells to be safe, well tolerated, and non-migratory. The Good Laboratory Practice (GLP) compliant studies are required prior to filing an IND. The safety studies will include several key areas of examination, including, tumorigenicity potential, cell tolerability, cell survival, general safety, and potential for biodistribution.
"We are pleased to complete this key milestone as we move our RPE program toward the clinic," said William Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Based upon our cell characterization data, pharmacology studies, and the overall safety profile, we are excited by the prospects for this program and the potential to treat a large unmet medical need. The successful completion of our Pre-IND meeting represents another step forward towards the filing of the IND for our RPE Program and ultimately bringing the therapy to the bedside. We are one step closer to bringing our second stem cell therapy to patients in need."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Dan Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.24 0 Advanced Cell Technology Announces Presentation of Results from Myoblast Study at ISCTR World Symposium
Feb 11, 2008 09:13:01 (ET)
LOS ANGELES, Feb 11, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that principal investigator Dr. Nabil Dib, M.D., M.Sc., FACC, presented results from a 23-patient study of ACT's myoblast therapy for the treatment of congestive heart failure (CHF) over the weekend at the International Society for Cardiovascular Translational Research (ISCTR) World Symposium in San Diego, CA. Dr. Dib presented the results as a case study of the successful translation of a therapy from scientific research to the bedside. The results of the study demonstrate long term cell survival in heart failure patients as well as strong quality of life improvements as measured by the New York Heart Association third party questionnaire, the Minnesota Living with Heart Failure Questionnaire, and the 6 minute walk results (compared to continued deterioration by the control group). Moreover, ACT's myoblast trial has been the only cell-based, FDA-approved human clinical trial that has not required the administration of anti-arrhythmic drugs or assist devices, which is in contrast to trials for bone marrow-derived and other adult stem cell therapies.
ISCTR is an annual meeting for basic and clinical scientist practicing cardiovascular disease research sponsored by the University California, San Diego, Catholic Healthcare West and the International Society for Cardiovascular Translational Research. Dr. Dib is Director, Clinical Cardiovascular Cell Therapy, University of California, San Diego, and Director of Cardiovascular Research of Catholic Health Care West's Chandler Regional Hospital and Mercy Gilbert Medical Center near, Phoenix, Arizona.
Dr. Dib enrolled 23 patients at Arizona Heart Institute with poor heart function and congestive heart failure. The control group consisted of 11 patients on standard drug therapy while the treatment group was given varying doses of 30, 100, 300, or 600 million autologous skeletal myoblast (ASM) cells. After one year, the myoblast therapy showed a favorable safety profile as compared to the control group. Likewise, secondary measures showed improvements in quality of life measures, improvements in measures of tissue regrowth and potential improvement in heart function, while the control group showed signs of heart failure progression on the same measures. The data from the study support conducting larger double-blind, placebo controlled studies. A Phase II human clinical trial has been reviewed and cleared to commence by the FDA. The planned Phase II trial will be conducted at multiple clinical centers across the country including in Arizona and California.
Patients with CHF due to myocardial infarction (damage in heart muscle) often have scar tissue in the heart, which limits the heart's ability to pump blood. In spite of optimal medical therapy and other current heart failure treatments, in the United States alone 2 million patients per year are admitted to the hospital for CHF and almost one-half million die annually. Doctors may now have the opportunity to successfully replace scarred heart tissue with healthy muscle via intracardiac injections of ASM stem cells from the skeletal muscle.
"In this study, we learned that ASM cell transplantation using a minimally invasive catheter system is safe, showed improvement in measures of quality of life, and may have the potential to improve cardiac function and electrical activity," said Dr. Dib. By using a catheter and transplanting ASM cells into scarred tissue, new living muscle can potentially be formed with limited risk to the patient. Since the transplanted stem cells are harvested from the patient's own skeletal muscles, the cells are compatible with the body, avoiding possible immune system and tissue compatibility complications. The procedure poses less risk than surgical procedures because no anesthesia is required and only a small incision is necessary for catheter access. Patients can be discharged within 24 hours of the procedure.
"We are honored that the ISCTR chose our myoblast therapy as the centerpiece for discussing how best to translate research from the bench to the bedside," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology, Inc. "We remain encouraged by the data Dr. Dib presented and believe the positive 12-month data represent another step in our process of initiating a Phase II human clinical trial for our myoblast therapy. We look forward to moving the myoblast and other stem cell therapies through the clinic and ultimately to patients in need of treatment." In addition to nearing the commencement of Phase II human clinical trials for the myoblast therapy, ACT recently completed a pre-IND meeting with the FDA for its RPE program for the treatment of retinal degenerative disease. Should ACT successfully file an IND for its RPE therapy, the company plans to move forward with Phase I human clinical trials, which would position ACT with two therapies in human clinical trials as well as a third, the hemangioblast program for the treatment of blood and cardiovascular indications, in preclinical trials.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Media: Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
ITEM 8.01 Other Events. Subject to market conditions, Advanced Cell Technology, Inc. (the "Company") plans to privately offer up to $3,000,000 of convertible promissory notes (the "Securities"). The Company is providing this report in accordance with Rule 135c of the Securities Act of 1933, as amended (the "Securities Act"). The timing of the closing of the offering will be subject to market conditions. The Company plans to use the net proceeds to fund working capital, including costs associated with planned clinical trials.
The financing is expected to be in the form of up to $3,000,000 principal amount of convertible promissory notes. The notes are expected to have a term of no more than 24 months and are anticipated to be convertible into the Company's common stock, with conversion prices based on market conditions. All terms are subject to market conditions and may vary materially from those set forth above. No assurance is given that the Company will be able to close the financing described herein, or that if a financing is closed that the terms and conditions of the financing will not differ materially from those described herein.
The offering will be conducted as a private placement made only to accredited buyers in accordance with Section 4(2) of the Securities Act. The Securities will not be registered under the Securities Act and may not be offered or sold without registration unless an exemption from such registration is available.
This notice is issued pursuant to Rule 135c of the Securities Act, and does not constitute an offer to sell the Securities, nor a solicitation for an offer to purchase the Securities.
Statements in this report regarding future financial and operating results, future growth in research and development programs, potential applications of the Company's technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect the Company's results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the Company's management at the time they are made, and the Company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ADVANCED CELL TECHNOLOGY, INC.
By: /s/ William M. Caldwell, IV William M. Caldwell, IV Chief Executive Officer
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.22 0.02 Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes (Liver Cells) From Human Embryonic Stem Cells
Feb 21, 2008 12:00:02 (ET)
WORCESTER, Mass., Feb 21, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) reported today for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells). The research, described online (ahead of print) in the journal STEM CELLS, signifies a significant step towards the efficient generation of hepatocytes for use in regenerative medicine and drug discovery. Moreover, the research represents another one of Advanced Cell Technology's efforts aimed at the large-scale differentiation of human embryonic stem cells (hESCs) into critical replacement cell types. In addition to demonstrating the efficient generation of hepatocytes in research published today, the company has made significant progress in the generation of retinal pigmented epithelial (RPE) cells to treat retinal degenerative diseases and the generation of hemangioblasts to treat vascular disease as well as to create a large-scale and donorless source of red blood cells and platelets.
Two hallmarks of embryonic stem cells, their versatility and capacity for unlimited self renewal, suggest the cells could serve as a potentially inexhaustible source of cells for replacement therapy. As with other tissues, there is a scarcity of donor livers and hepatocytes, which is compounded by the low recovery and proliferative capacity of adult hepatocytes. In addition to the cells' potential use for the treatment of liver disease, hESC-derived hepatocytes could also provide a valuable model for novel pharmaceutical drug discovery assays as well as new drug metabolism and cytotoxicity screens, particularly because the liver is a major site for detoxification.
"We have established a highly-efficient method for deriving hepatocytes from stem cells that mirrors events in embryonic development," said Robert Lanza, M.D., Chief Scientific Officer at Advanced Cell Technology, Inc. and senior author of the study. "Large scale production of hepatocytes using this method should greatly bolster their applications in basic research, clinical medicine and preclinical drug discovery."
The method reported yielded synchronous populations of hepatocytes that were generated in clinically preferred conditions with minimum use of serum and cell feeders. Highly enriched populations of definitive endoderm (DE) were generated from hESCs and then induced to differentiate along the hepatic lineage by the sequential addition of inducing factors implicated in physiological hepatogenesis. The differentiation process was largely uniform with cell cultures progressively expressing increasing numbers of hepatic lineage markers. The hepatocytes exhibited functional hepatic characteristics such as glycogen storage, indocyanine green uptake and release, and albumin secretion. In an animal model of acute liver injury, the hESC-DE cells differentiated into hepatocytes and successfully repopulated the damaged liver.
"I am delighted with the tremendous progress our scientists are making to generate a variety of important functional cells types and refine our cell differentiation process," stated William M. Caldwell IV, CEO and Chairman of Advanced Cell Technology. "These cells have the potential to benefit many Americans suffering from serious and potentially life-threatening diseases with few if any alternatives. We are committed to developing new methods to help translate our stem cell technology into the clinic and are seeking partners for some of our newest scientific advances."
Other authors on the paper were Dr. Sadhana Agawal (first author of the study) and Katherine Holton, a senior research associate at Advanced Cell Technology, Inc.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Pharming concludes license agreement with Advanced Cell Technology
Feb 28, 2008 12:07:29 (ET)
LEIDEN, THE NETHERLANDS, Feb 28, 2008 (MARKET WIRE via COMTEX) -- Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that it has concluded a license agreement with Advanced Cell Technology Inc to obtain exclusive rights on patents in the field of transgenic technology, to which it already had non-exclusive rights. Financial details of the agreement were not disclosed.
These patents were previously owned by Infigen Inc and cover a wide range of technologies including for Pharming relevant elements of nuclear transfer, which is an essential step in generating transgenic cattle. The agreement provides Pharming strict control over the generation of its transgenic cattle, while, at the same time, increasing the barriers of entry for others.
Protecting its technology platforms via patents and licenses is an essential element of Pharming's strategy. This is done not only to maintain 'freedom to operate', but also to limit others in using the technology without a license, thereby protecting the investments that Pharming has made in developing its technology.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin(R) (recombinant human C1 inhibitor) for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with Novathera) and DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl .
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
Copyright Copyright Hugin AS 2008. All rights reserved.
Contact:
Rein Strijker (NL) Pharming Group NV T: +31 (0)71 52 47 400
SOURCE: Pharming Group N.V.
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology, Inc. Enters into License Agreement with Pharming Group N.V.
Feb 29, 2008 07:38:01 (ET)
LOS ANGELES, Feb 29, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has entered into an agreement with Pharming Group N.V. giving Pharming an exclusive, global license to non-human use of certain patents associated with but not limited to oocyte activation patents held by Advanced Cell Technology. According to the terms of the license agreement, Pharming will pay Advanced Cell Technology a one-time license fee. Prior, Pharming had a nonexclusive license to these patents. Based in the Netherlands, Pharming Group N.V. is focused on developing treatments for genetic and aging diseases, specialty products for surgical indications, and intermediates for various applications and nutritional products.
Advanced Cell Technology has been focused on building a broad intellectual property portfolio since its inception. In early 2007, the company strengthened its IP portfolio by acquiring the intellectual property assets of its former competitor Infigen, Inc. relating to somatic cell nuclear transfer, parthenogenesis, and other related technologies. Upon the closing of its Mytogen, Inc. acquisition later that year, ACT absorbed Mytogen's patent portfolio as well. Advanced Cell Technology now owns or has exclusive licenses to over 380 patents and patent applications worldwide in the field of regenerative medicine and stem cell therapy. In addition, ACT has non-exclusive rights to a portfolio of patents and patent applications that support its core intellectual property.
"We are pleased to be able to monetize our intellectual property portfolio in a number of ways," stated William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "Our intellectual property and the research and science that our employees perform remain the foundation of our company. Using this foundation as a basis for developing commercial therapeutics and entering into licensing agreements allows us to finance the company in profitable and nondilutive manners. We plan on continuing to leverage our IP portfolio."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology Announces Catheter Supply Agreement with Biologics Delivery Systems Group
Mar 5, 2008 08:00:10 (ET)
LOS ANGELES, Mar 05, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has reached a supply agreement with Biologics Delivery Systems Group, Cordis Corporation (a Johnson & Johnson company), in which Biologics Delivery Systems will supply catheters for the Phase II human clinical trial of ACT's myoblast therapy for the treatment of heart failure. Advanced Cell Technology's myoblast therapy successfully completed Phase I human clinical trials in 2007 utilizing the therapy safely in more than forty patients. Safety of the therapy was demonstrated in four independent studies. The U.S. Food and Drug Administration has given the company clearance to proceed with Phase II human clinical trials. The company expects its Phase II human clinical trial (CAuSMIC II) to begin shortly.
ACT's myoblast therapy involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter-based procedure. Over one million new patients with heart attacks are treated annually in the United States alone, representing a multi-billion dollar market opportunity. Current therapies do not result in rebuilding of heart muscle and do not prevent progression of congestive heart failure, poor quality of life, and long-term deterioration. According to the National Heart, Lung, and Blood Institute, a division of the National Institutes of Health, approximately 5 million people in the United States have congestive heart failure and an estimated 400,000 new cases are diagnosed each year. Roughly 50% of CHF patients die within 5 years.
The Phase II human clinical trial will be a multi-center study following a similar protocol to the one used in the company's Phase I study. That study demonstrated safety and evidence of significant heart function improvement in congestive heart failure patients as a result of the implantation of the ACT's proprietary autologous skeletal myoblasts using the Biologics Delivery Systems NOGA(R) Cardiac Navigation System and MyoStar(R) Injection Catheter. "The NOGA(R) System created highly precise, three-dimensional images of the heart. These images gave us a clear 'map' that helped us to successfully deliver the adult stem cells where we intended them to go," commented Dr. Nabil Dib, the lead investigator for the myoblast phase I study. "This imaging technology was critical to making this study possible." The Phase II human clinical trial will use the latest generation catheters provided as a result of ACT's ongoing relationship with the Biologics Delivery Systems.
"The supply commitment for NOGA mapping and Myostar injection catheters from Biologics Delivery Systems Group represents another step toward commercializing our myoblast therapy and bringing novel treatment to patients with few effective alternatives," commented William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We are excited to commence our Phase II human clinical trials soon."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology and Catholic Healthcare West Sign Clinical Agreement
Mar 12, 2008 09:15:01 (ET)
LOS ANGELES, Mar 12, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACT) (ACTC, Trade ) announced today that it has signed a clinical trial agreement with Chandler Regional Medical Center and Mercy Gilbert Medical Center, members of Catholic Healthcare West (CHW), the nation's eighth largest healthcare system, to become ACT's first clinical trial sites for the Phase II myoblast study. In addition, CHW has received Institutional Review Board approval for the clinical trial, which is expected to begin soon. ACT's myoblast program is an autologous adult stem cell therapy for the treatment of heart disease that has successfully completed four Phase I clinical trials and received clearance from the Food and Drug Administration to begin Phase II trials.
In November 2007, ACT and CHW announced that the two parties had entered into a letter of intent for a proposed exclusive business arrangement to establish a clinical trial research site and a North American regenerative medicine interventional cardiology training center for the Phase II clinical trial. The study, which will utilize 3-Dimensional Guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ishemic Cardiomyopathy (CAuSMIC), will soon be open for enrollment. Led by principal investigator Nabil Dib, M.D., M.Sc., F.A.C.C., director of Cardiovascular Research for Chandler Regional Medical Center and Mercy Gilbert Medical Center, enrollment in the CAuSMIC trial will focus on patients who are not eligible for angioplasty or coronary artery bypass surgery, and who continue to have poor quality of life despite receiving optimal medical therapy or cardiac resynchronization therapy with a pacemaker or defibrillator device.
"The agreement with CHW signifies our readiness to begin the Phase II clinical trial," said William M. Caldwell, IV, chairman and CEO of ACT. "We are excited to begin the trial, which has the potential to be a major advance for the field of regenerative medicine and, more importantly, to patients in need of care. We look forward to working with such a prominent healthcare group."
"Currently, there are no treatment options available to correct heart failure, only those that can slow its progression," said David G. Covert, president and CEO of the CHW East Valley Service Area and Chandler Regional Medical Center. According to Covert, Dr. Dib's findings are the culmination of seven years of prior clinical work to demonstrate the safety and utility of taking a patient's own muscle stem cells to repair heart muscle damage. "Chandler Regional Medical Center and Mercy Gilbert Medical Center are proud to participate in developing this innovative treatment option for people living with heart failure. As we continue to develop our research program, our main focus is to translate this type of research into bedside standard of care."
About Catholic Healthcare West
Catholic Healthcare West (CHW) is the eighth largest hospital system in the nation and one of the largest not-for-profit hospital providers in the West. Founded in 1986, the CHW network of more than 8,500 physicians and approximately 50,000 employees serve a population spanning 22 million people at 43 hospitals across California, Arizona, and Nevada. CHW is committed to delivering compassionate, high-quality, affordable healthcare services with special attention to the poor and underserved. In fiscal year 2007, CHW provided $922 million in charity care, community benefits, and unreimbursed patient care. CHW facilities in Arizona include Chandler Regional Medical Center, Mercy Gilbert Medical Center, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, CHW Urgent Cares in Ahwatukee, Gilbert and Queen Creek, Sun Lakes Laboratory, Warner Outpatient Surgery and the Arizona Orthopedic Surgical Hospital. For more information, please visit our Website at www.chwHEALTH.org .
About Chandler Regional Medical Center
Chandler Regional Medical Center is a 225-bed, acute-care, non-for-profit provider of emergency care, maternal child services, cardiovascular services, wound healing, cancer treatment, diabetes treatment, and diagnostic services. It is located at 475 S. Dobson Road (corner of Dobson Road and Frye Road) in Chandler. For more information, please visit www.chandlerregional.org or call (480) 728-3000. Chandler Regional Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-3424.
About Mercy Gilbert Medical Center
Mercy Gilbert Medical Center is located at the intersection of Val Vista Drive and Loop 202 (south of Pecos Road and east of Val Vista Drive). Mercy Gilbert Medical Center is a four-story, full-service acute-care facility with 182 beds. For more information, please visit www.mercygilbert.org or call (480) 728-8000. Mercy Gilbert Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-8396.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
LOS ANGELES, Mar 31, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it completed a private placement with institutional and other accredited investors. The company intends to use the proceeds of the offering towards for general corporate purposes, including additions to working capital, and to finance the further development of the company's clinical programs.
Advanced Cell Technology closed on the private placement of $3,855,360 principal amount of amortizing senior secured convertible debentures. The issuance of the debentures generated $3,072,000 in gross proceeds.
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "This transaction represents a significant event for Advanced Cell Technology and reflects the growing recognition of the potential of the company's stem cell technology. The proceeds from this financing will allow ACTC to accelerate its development programs focused on novel therapies for diseases and indications that have few medical alternatives. Cardiovascular disease and regenerative retinal disorders represent substantial unmet medical needs that we believe our cell based therapies address."
Additional details regarding the financing will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Dan Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology to be Featured Tonight on ABC Television's Special Report ''Live to 150, Can You Do It? Secrets to Living Longer''
Apr 1, 2008 08:30:07 (ET)
LOS ANGELES, Apr 01, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that the company will be featured on ABC Television's special report titled, "Live to 150, Can You Do It? Secrets to Living Longer," hosted by Barbara Walters. The report is scheduled to air tonight on ABC Television throughout the country at 10 PM eastern time. The report will include an interview with Dr. Robert Lanza, MD, Chief Scientific Officer at Advanced Cell Technology. During the interview, Dr. Lanza and Ms. Walters will discuss a number of Advanced Cell Technology's research platforms including its blastomere program for creating human embryonic stem cell (hESC) lines without impacting the developmental potential of embryos as well as the company's research into developing a universal O negative red blood cell bank using human embryonic stem cell science.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
If I'm not mistaken this stock was at about .70 a year ago. I guess .13 is a good buy in point cosidering it's going to be highlighted tonite by Baba Wawa... I'm in for 20K shares to start. Lets see what happens this week. GL
Posts: 235 | Registered: Jan 2007
| IP: Logged |
posted
I smacked the ask. IMAKE keeps this one goin pretty good!! lmao!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
hdsn acting like a magnet took everyone to .125
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
nite taking back over.. tomorrow should be interesting.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Double bottom bouncer - 3 month chart. Gotta eat through more convertibles GRRRRRRR!!
On ABC 10PM tonight!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Quick notes from the presentation... -Cloned the first endangered animal - the wild ox, as well as a herd of cows - said to possibly be the longest living cows on the planet. - New blood created from stem cells - Universal blood type. -Manufacturing heart valves, arteries and muscles
other foot notes to follow up on Sirtris (not actc but something I need to research). Also Dr. Darvis Taylor from the University of Minnesota.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Barbara Walters' ABC Network Television Special Highlights Role that Advanced Cell Technology's Embryonic Stem Cells Play in Preventing Aging
Apr 2, 2008 07:30:02 (ET)
LOS ANGELES, Apr 02, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that an ABC Television's special report titled, "Live to 150, Can You Do It? Secrets to Living Longer," which aired last night and was hosted by Barbara Walters, highlighted the role that the company's blastomere program for creating human embryonic stem cell (hESC) lines without impacting the developmental potential of embryos could play in extending life and slowing down the aging process. The special also highlighted Advanced Cell Technology's research into developing a universal O negative red blood cell bank using human embryonic stem cell science. The report, which included an interview with Dr. Robert Lanza, MD, Chief Scientific Officer at Advanced Cell Technology, featured the company's research platforms and included a discussion of the role that the company's stem cell science could play in treating various diseases.
The show profiled the lives of several people who are currently 100 years old or older and described some of the most promising scientific developments that could extend life. Advanced Cell Technology's technology platform was included among the scientific breakthroughs.
In August 2006, Advanced Cell Technology reported in the journal Nature that company scientists had successfully generated hESCs using its blastomere technology, an approach that does not destroy the developmental potential of embryos. The blastomere technology has been reproduced and peer-reviewed on several occasions. In June 2007, ACT announced at the fifth annual meeting of the International Society for Stem Cell Research in Cairns, Australia, that it had reproduced its work by successfully producing an hESC line without destroying an embryo at its lab in Worcester, Massachusetts. In January 2008, ACT together with colleagues announced the development of five hESC lines without the destruction of embryos. The method was published in the journal Cell Stem Cells, published by Cell Press. The peer-reviewed technique was initially carried out by ACT scientists under the direction of Dr. Lanza and then independently replicated by scientists on the West Coast. In addition, the NIH announced in 2007 that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus." ACT's blastomere program was cited by the NIH as an alternative method in its implementation plan; therefore, should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.
In addition to its blastomere research platform, Advanced Cell Technology has made progress on the therapeutic front. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. Finally, ACT's Myoblast program, an autologous adult stem cell therapy for the treatment of heart disease, has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
quote:Originally posted by Happy Valley: In a few at .092...Trying to catch the knife...lol
averaged out. Convertibled are killing this thing.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
I did. Prolly for the last time. Convertibles were re-written. And I was thinking they would at least stick to their price. Still could get a pop IMAKE, was thinking it would. ----------------------------------- · The Conversion Price set forth in each outstanding 2005 debenture, 2006 debenture, and 2007 debenture held by Prior Purchasers who participated in the 2008 Financing was reset to $0.15;
· The Exercise Price set forth in each outstanding 2005 warrant, 2006 warrant, and 2007 warrant held by Prior Purchasers who participated in the 2008 Financing was reset to $0.165; and
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
lotta buys going thru now at .105 and then one sell takes it back to .103.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
you would thing barbara waa waa could have done this stock some good , i mean what more do you want for a stock to shoot through the roof. A tv show all sorts of good news cows that will live forever I dont know what to do anymore.
-------------------- "The Stock Market Roller Coaster is my favorite ride at the park" Posts: 211 | From: MN | Registered: Mar 2008
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Good Luck]](graemlins/goodluck.gif)
![[Were Up]](graemlins/wereup.gif)
